Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3115138 | 0.78 | ALDH1A1 (0.32) | ALDH1A1TSHR | |
| SCHEMBL19874837 | 0.77 | ALDH1A1 (0.38) | ALDH1A1TET2DGAT1EGLN1 | |
| SCHEMBL15804065 | 0.76 | ALDH1A1 (0.33) | ALDH1A1TET2KEAP1NFE2L2HCAR2 | |
| SCHEMBL321582 | 0.75 | DGAT1 (0.52) | ALDH1A1TET2DGAT1EGLN1 | |
| SCHEMBL28433326 | 0.75 | DGAT1 (0.41) | ALDH1A1TET2DGAT1EGLN1 | |
| SCHEMBL4784315 | 0.73 | DGAT1 (0.39) | ALDH1A1DGAT1 | |
| SCHEMBL486217 | 0.73 | ALDH1A1 (0.41) | ALDH1A1TET2EGLN1KEAP1NFE2L2 | |
| SCHEMBL5838619 | 0.73 | FKBP1A (0.40) | ALDH1A1TET2DGAT1EGLN1TSHR | |
| SCHEMBL6950834 | 0.71 | ALDH1A1 (0.56) | ALDH1A1TET2EGLN1KEAP1NFE2L2 | |
| SCHEMBL348208 | 0.71 | TSHR (0.40) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121378163-A | Preparation method of 4-amino-6-tert-butyl-3-mercapto-1, 2, 4-triazine-5 (4H) -ketone | 青岛科技大学 | 2026-01-23 | — | — | CN | disclosed |
| US-11655314-B2 | Photoinitiators for light-curable compositions | TECHNISCHE UNIVERSITAET WIEN (AT) | 2023-05-23 | — | — | US | disclosed |
| US-11655314-B2 | Photoinitiators for light-curable compositions | TECHNISCHE UNIVERSITAET WIEN (AT) | 2023-05-23 | — | — | US | disclosed |
| US-11518823-B2 | Photoinitiators for light-curable compositions | TECHNISCHE UNIVERSITAET WIEN (AT) | 2022-12-06 | — | — | US | disclosed |
| US-20220235153-A1 | PHOTOINITIATORS FOR LIGHT-CURABLE COMPOSITIONS | TECHNISCHE UNIVERSITAET WIEN (AT) | 2022-07-28 | — | — | US | disclosed |
| US-11193157-B2 | Processes using amino acid dehydrogenases and ketoreductase-based cofactor regenerating system | CODEXIS, INC. (US) | 2021-12-07 | — | — | US | disclosed |
| US-20200231531-A1 | PHOTOINITIATORS FOR LIGHT-CURABLE COMPOSITIONS | TECHNISCHE UNIVERSITAET WIEN (AT) | 2020-07-23 | — | — | US | disclosed |
| US-20200181672-A1 | PROCESSES USING AMINO ACID DEHYDROGENASES AND KETOREDUCTASE-BASED COFACTOR REGENERATING SYSTEM | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2020-06-11 | — | — | US | disclosed |
| US-10604781-B2 | Processes using amino acid dehydrogenases and ketoreductase-based cofactor regenerating system | CODEXIS, INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190112630-A1 | PROCESSES USING AMINO ACID DEHYDROGENASES AND KETOREDUCTASE-BASED COFACTOR REGENERATING SYSTEM | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2019-04-18 | — | — | US | disclosed |
| US-20050228044-A1 | Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders | MERCK SHARP & DOHME CORP. | 2005-10-13 | — | — | US | disclosed |
| EP-1539136-A2 | PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS | Merck & Co., Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040087569-A1 | N-heterocyclic bicyclic lactone compounds | NELSON TODD D (US) | 2004-05-06 | — | — | US | disclosed |
| WO-2004010936-A2 | PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS | MERCK & CO., INC. (US) | 2004-02-05 | — | — | WO | disclosed |
| US-6583312-B2 | Catalytic hydrogenation of trimethylpyruvic acid | BAYER AKTIENGESELLSCHAFT (DE) | 2003-06-24 | — | — | US | disclosed |
| US-20020035271-A1 | Process for preparing oprtically active trimethyllactic acid and its ester | BAYER AKTIENGESELLSCHAFT (DE) | 2002-03-21 | — | — | US | disclosed |
| US-6348617-B1 | REACTING PYRUVIC ACID COMPOUND IN WATER WITH AMMONIUM OR ALKALI METAL BISULFITE TO GIVE AQUEOUS SOLUTION OF BISULFITE ADDUCT, ISOLATING BY PHASE SEPARATION, OPTIONALLY USING HYDROPHOBIC SOLVENT, CONTACTING WITH ACID TO DECOMPOSE ADDUCT | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-02-19 | — | — | US | disclosed |
| EP-0937703-A1 | METHOD FOR PURIFYING PYRUVIC ACID COMPOUNDS | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1999-08-25 | — | — | EP | disclosed |
| CN-87106076-A | Hydantoin derivative and be the weedicide of effective ingredient with this derivative | — | 1988-08-31 | — | — | CN | disclosed |
| US-4698333-A | Use of substituted malonic acid derivatives as agents for combating pests | BAYER AKTIENGESELLSCHAFT (DE) | 1987-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655314-B2 | Photoinitiators for light-curable compositions | OXER1, PPOX, ORC3 | ALDH1A1 901/4885TET2 2768/4885DGAT1 3297/4885 |
| US-11518823-B2 | Photoinitiators for light-curable compositions | OXER1, ORC3, PPOX | ALDH1A1 874/4885TET2 2904/4885DGAT1 3300/4885 |
| US-20040087569-A1 | N-heterocyclic bicyclic lactone compounds | VIP, NGLY1, NPPA | ALDH1A1 2305/4885TET2 4131/4885DGAT1 3633/4885 |
| US-20050228044-A1 | Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders | PPARD, PPARA, PPARG | ALDH1A1 426/4885TET2 4798/4885DGAT1 70/4885 |
| US-20020035271-A1 | Process for preparing oprtically active trimethyllactic acid and its ester | ME1, OPRK1, OPRM1 | ALDH1A1 2551/4885TET2 459/4885DGAT1 1757/4885 |
| US-20220235153-A1 | PHOTOINITIATORS FOR LIGHT-CURABLE COMPOSITIONS | OXER1, PPOX, ORC3 | ALDH1A1 901/4885TET2 2768/4885DGAT1 3297/4885 |
| US-20200231531-A1 | PHOTOINITIATORS FOR LIGHT-CURABLE COMPOSITIONS | OXER1, ORC3, PPOX | ALDH1A1 874/4885TET2 2904/4885DGAT1 3300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.